NO333017B1 - Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. - Google Patents
Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne.Info
- Publication number
- NO333017B1 NO333017B1 NO20043401A NO20043401A NO333017B1 NO 333017 B1 NO333017 B1 NO 333017B1 NO 20043401 A NO20043401 A NO 20043401A NO 20043401 A NO20043401 A NO 20043401A NO 333017 B1 NO333017 B1 NO 333017B1
- Authority
- NO
- Norway
- Prior art keywords
- igfbp
- cancer
- antisense oligonucleotide
- seq
- antisense
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title claims abstract description 53
- 238000012230 antisense oligonucleotides Methods 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract description 25
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 title description 46
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 title description 46
- 238000000034 method Methods 0.000 title description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000001105 regulatory effect Effects 0.000 claims abstract description 15
- 230000000295 complement effect Effects 0.000 claims abstract description 14
- 230000002124 endocrine Effects 0.000 claims abstract description 14
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract description 5
- 102000050770 human IGFBP2 Human genes 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 101000840566 Homo sapiens Insulin-like growth factor-binding protein 5 Proteins 0.000 claims abstract description 3
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims description 47
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims description 47
- 108091034117 Oligonucleotide Proteins 0.000 claims description 47
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 abstract description 17
- 210000004027 cell Anatomy 0.000 description 28
- 239000003098 androgen Substances 0.000 description 19
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 11
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 11
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000003780 Clusterin Human genes 0.000 description 2
- 108090000197 Clusterin Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000010225 mixed cell type cancer Diseases 0.000 description 2
- 208000029638 mixed neoplasm Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35004602P | 2002-01-17 | 2002-01-17 | |
| PCT/CA2003/000061 WO2003062421A1 (en) | 2002-01-17 | 2003-01-17 | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043401L NO20043401L (no) | 2004-10-13 |
| NO333017B1 true NO333017B1 (no) | 2013-02-18 |
Family
ID=27613360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043401A NO333017B1 (no) | 2002-01-17 | 2004-08-16 | Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. |
Country Status (15)
| Country | Link |
|---|---|
| US (11) | US20030158143A1 (ja) |
| EP (1) | EP1465995B1 (ja) |
| JP (1) | JP4491240B2 (ja) |
| KR (2) | KR101265180B1 (ja) |
| AT (1) | ATE402999T1 (ja) |
| AU (1) | AU2003237616B2 (ja) |
| CA (1) | CA2469685C (ja) |
| DE (1) | DE60322509D1 (ja) |
| DK (1) | DK1465995T3 (ja) |
| ES (1) | ES2307942T3 (ja) |
| HU (1) | HU229452B1 (ja) |
| IL (2) | IL162540A0 (ja) |
| NO (1) | NO333017B1 (ja) |
| NZ (1) | NZ533126A (ja) |
| WO (1) | WO2003062421A1 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534773B1 (en) | 1999-02-26 | 2009-05-19 | The University Of British Columbia | TRPM-2 antisense therapy |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| EP1465995B1 (en) | 2002-01-17 | 2008-07-30 | The University of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| WO2004018676A2 (en) | 2002-08-21 | 2004-03-04 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
| EP1530636B1 (en) * | 2002-08-21 | 2010-08-18 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| AU2003297259A1 (en) * | 2002-11-14 | 2004-06-03 | Wyeth | Methods and compositions for treating neurological disorders |
| WO2005030260A1 (en) * | 2003-10-01 | 2005-04-07 | The University Of British Columbia | Bispecific oligonucleotide for the treatment of cns malignancies |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| JP4980919B2 (ja) * | 2004-11-23 | 2012-07-18 | ザ ユニバーシティー オブ ブリティッシュ コロンビア ユニバーシティー−インダストリー リエゾン オフィス | Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 |
| US7315916B2 (en) * | 2004-12-16 | 2008-01-01 | Sandisk Corporation | Scratch pad block |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| US8329399B2 (en) * | 2006-10-27 | 2012-12-11 | Siu K W Michael | Endometrial biomarkers |
| DK2504363T3 (da) | 2009-11-24 | 2019-07-29 | Alethia Biotherapeutics Inc | Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen |
| JP6017964B2 (ja) | 2010-03-01 | 2016-11-02 | ティーエーユー・セラピューティクス・エルエルシー | 癌診断および撮像 |
| AU2012257487A1 (en) * | 2011-05-19 | 2014-01-16 | Teva Pharmaceutical Industries Ltd. | Method for treating non-small cell lung cancer |
| SG11201400526TA (en) | 2011-09-12 | 2014-04-28 | Tau Therapeutics Llc | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| EP2817028A4 (en) | 2012-02-22 | 2015-11-04 | Alethia Biotherapeutics Inc | COMMON USE OF A CLUSTERIN INHIBITOR AND EGFR INHIBITOR FOR TREATING CANCER |
| CA2844640A1 (en) * | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
| WO2017066643A1 (en) | 2015-10-14 | 2017-04-20 | Bio-Path Holding, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP6957460B2 (ja) | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | アンジェルマン症候群および関連する障害の処置方法 |
| US10496215B2 (en) * | 2016-04-29 | 2019-12-03 | Synaptics Incorporated | Sensing for touch and force |
| MX2019003070A (es) | 2016-09-16 | 2019-10-14 | Bio Path Holdings Inc | Terapia de combinacion con oligonucleotidos antisentido liposomales. |
| JP7134178B2 (ja) | 2017-02-15 | 2022-09-09 | カビオン・インコーポレイテッド | カルシウムチャネル阻害剤 |
| SG11201909336VA (en) | 2017-04-19 | 2019-11-28 | Bio Path Holdings Inc | P-ethoxy nucleic acids for stat3 inhibition |
| MX2019012818A (es) | 2017-04-26 | 2020-07-14 | Cavion Inc | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. |
| KR102068302B1 (ko) | 2018-07-25 | 2020-01-20 | 정준모 | 봉투 고정장치 |
| TW202027728A (zh) | 2018-10-03 | 2020-08-01 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992003471A1 (en) | 1990-08-28 | 1992-03-05 | Chiron Corporation | New insulin-like growth factor binding protein igfbp-5 |
| EP0546074B1 (en) | 1990-08-28 | 2001-11-14 | Chiron Corporation | Genetic material encoding igfbp-5 |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) * | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| EP0736093B1 (en) * | 1993-12-23 | 2003-03-19 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| DK0882061T3 (da) * | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
| US5910583A (en) * | 1996-11-04 | 1999-06-08 | Duke University | Antisense oligonucleotides against ERBB-2 |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| NZ527718A (en) | 1998-11-19 | 2004-11-26 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| AU3116800A (en) | 1998-12-11 | 2000-06-26 | Research Foundation Of The State University Of New York, The | Compositions and methods for altering cell migration |
| US7534773B1 (en) * | 1999-02-26 | 2009-05-19 | The University Of British Columbia | TRPM-2 antisense therapy |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| WO2000069454A1 (en) * | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
| NZ515964A (en) * | 1999-06-21 | 2004-03-26 | Murdoch Childrens Res Inst | A method for the prophylaxis and/or treatment of medical disorders |
| DE60028970T2 (de) | 1999-07-02 | 2007-02-15 | Genentech Inc., San Francisco | An her2 bindende peptidverbindungen |
| ATE393220T1 (de) * | 1999-07-19 | 2008-05-15 | Univ British Columbia | Antisense-therapie für hormonregulierte tumoren |
| US6310047B1 (en) * | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
| MXPA02006167A (es) | 1999-12-21 | 2004-02-26 | Univ Yale | Promocion de la angiogenesis con survivina. |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| DK1309726T4 (en) * | 2000-03-30 | 2019-01-28 | Whitehead Inst Biomedical Res | RNA Sequence-Specific Mediators of RNA Interference |
| CA2421087C (en) * | 2000-09-14 | 2012-03-27 | Martin Gleave | Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| CZ308053B6 (cs) * | 2000-12-01 | 2019-11-27 | Max Planck Gesellschaft | Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití |
| EP1390472A4 (en) * | 2001-05-29 | 2004-11-17 | Sirna Therapeutics Inc | NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS |
| US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| DE10152005A1 (de) | 2001-10-22 | 2003-04-30 | Bayer Cropscience Ag | Pyrazolylsubstituierte Heterocyclen |
| US20050123896A1 (en) | 2001-10-25 | 2005-06-09 | Benz Christopher C. | Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby |
| EP1465995B1 (en) * | 2002-01-17 | 2008-07-30 | The University of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| CA2485589A1 (en) * | 2002-05-14 | 2003-11-27 | Baylor College Of Medicine | Small molecule inhibitors of her2 expression |
| WO2004018676A2 (en) * | 2002-08-21 | 2004-03-04 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
| EP1530636B1 (en) | 2002-08-21 | 2010-08-18 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| WO2005030260A1 (en) * | 2003-10-01 | 2005-04-07 | The University Of British Columbia | Bispecific oligonucleotide for the treatment of cns malignancies |
| KR20120107456A (ko) * | 2009-07-30 | 2012-10-02 | 안티센스 파마 게엠베하 | 화학요법제와 티지에프-베타 시스템의 억제제의 조합 |
-
2003
- 2003-01-17 EP EP20030731644 patent/EP1465995B1/en not_active Expired - Lifetime
- 2003-01-17 WO PCT/CA2003/000061 patent/WO2003062421A1/en active Application Filing
- 2003-01-17 AT AT03731644T patent/ATE402999T1/de active
- 2003-01-17 NZ NZ533126A patent/NZ533126A/en not_active IP Right Cessation
- 2003-01-17 JP JP2003562288A patent/JP4491240B2/ja not_active Expired - Fee Related
- 2003-01-17 DE DE60322509T patent/DE60322509D1/de not_active Expired - Lifetime
- 2003-01-17 ES ES03731644T patent/ES2307942T3/es not_active Expired - Lifetime
- 2003-01-17 KR KR1020047011085A patent/KR101265180B1/ko not_active IP Right Cessation
- 2003-01-17 IL IL16254003A patent/IL162540A0/xx unknown
- 2003-01-17 CA CA 2469685 patent/CA2469685C/en not_active Expired - Fee Related
- 2003-01-17 DK DK03731644T patent/DK1465995T3/da active
- 2003-01-17 HU HU0402543A patent/HU229452B1/hu not_active IP Right Cessation
- 2003-01-17 AU AU2003237616A patent/AU2003237616B2/en not_active Ceased
- 2003-01-17 KR KR1020117003991A patent/KR101166214B1/ko not_active IP Right Cessation
- 2003-01-17 US US10/346,493 patent/US20030158143A1/en not_active Abandoned
-
2004
- 2004-06-15 IL IL16254004A patent/IL162540A/en active IP Right Grant
- 2004-08-16 NO NO20043401A patent/NO333017B1/no not_active IP Right Cessation
-
2005
- 2005-11-23 US US11/287,334 patent/US7973017B2/en not_active Expired - Fee Related
-
2008
- 2008-04-25 US US12/109,747 patent/US7928082B2/en not_active Expired - Fee Related
-
2010
- 2010-04-01 US US12/752,581 patent/US9101646B2/en not_active Expired - Fee Related
- 2010-12-27 US US12/978,940 patent/US8389491B2/en not_active Expired - Fee Related
-
2011
- 2011-04-15 US US13/087,627 patent/US8470796B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,618 patent/US8252765B2/en not_active Expired - Fee Related
-
2012
- 2012-05-11 US US13/469,402 patent/US8541390B2/en not_active Expired - Fee Related
- 2012-10-11 US US13/649,654 patent/US8580761B2/en not_active Expired - Fee Related
-
2013
- 2013-05-29 US US13/904,457 patent/US8835401B2/en not_active Expired - Fee Related
-
2015
- 2015-07-02 US US14/790,293 patent/US20160002630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333017B1 (no) | Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. | |
| AU2003237616A1 (en) | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same | |
| US7297684B1 (en) | Antisense therapy for hormone-regulated tumors | |
| JP4874503B2 (ja) | 前立腺及びその他の内分泌腺腫瘍治療のためのアンチセンス・インシュリン様成長因子結合蛋白質（ｉｇｆｂｐ）−２オリゴデオキシヌクレオチド | |
| AU2001290920A1 (en) | Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy | |
| US7491816B2 (en) | Antisense therapy for hormone-regulated tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |